CRBU
Caribou Biosciences, Inc.
Key Financials
Net Income
$-148125000
↑ 0.7%
Total Liabilities
$53.2M
↓ 11.9%
EPS (Diluted)
$-1.59
↑ 3.6%
Revenue
$11.2M
↑ 11.7%
Operating Income
$-148344000
↑ 11.0%
Cash & Equivalents
$12.4M
↓ 24.1%
Operating Cash Flow
$-110992000.00
↑ 19.7%
Total Assets
$175.4M
↓ 44.0%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 10-Q | 8/13/2026 | View on SEC |
| 8-K | 8/13/2026 | View on SEC |
| SCHEDULE 13G | 7/27/2026 | View on SEC |
| 8-K | 6/18/2026 | View on SEC |
| 8-K | 6/11/2026 | View on SEC |
| DEFA14A | 6/5/2026 | View on SEC |
| 10-Q | 5/7/2026 | View on SEC |
| 8-K | 5/7/2026 | View on SEC |
| DEFR14A | 5/1/2026 | View on SEC |
| ARS | 4/24/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | CRBU |
| Company Name | Caribou Biosciences, Inc. |
| CIK | 1619856 |
| Sector | Biological Products, (No Diagnostic Substances) |
| Industry | Non-accelerated filer Smaller reporting company Emerging growth company |
| Exchange | Nasdaq |
| SIC Code | 2836 |
| SIC Description | Biological Products, (No Diagnostic Substances) |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 510-982-6030 |